Etablissement Français du Sang (EFS) Île-de-France, Hôpital Henri-Mondor, F-94000 Créteil, France.
INSERM U955 Équipe Pirenne "Transfusion et Maladies du Globule Rouge" et Institut Mondor de Recherche Biomédicale (IMRB), F-94000 Créteil, France.
Biomolecules. 2021 Jun 30;11(7):963. doi: 10.3390/biom11070963.
Blood transfusion remains a key treatment for managing occlusive episodes and painful crises in sickle-cell disease (SCD). In that clinical context, red blood cells (RBCs) from donors and transfused to patients, may be affected by plasma components in the recipients' blood. Senescence lesion markers appear on the red cells after transfusion, shortening the RBC lifespan in circulation. In the specific context of SCD, senescence signals can also trigger the occlusive painful events, typical of the disease. This work follows through our previous data that described a RBC senescence process, rapidly detected after challenge with SCD pathological plasmas. In this clinical context, we wanted here to further explore the characteristics and physiologic consequences of AA RBC lesions associated with senescence, as lesions caused by RBCs after transfusion may have adverse consequences for SCD patients.
Plasma samples from SCD patients, with acute symptoms ( = 20) or steady-state disease ( = 34) were co-incubated with donor AA RBCs from blood units for 24 to 48 h. Specific markers signing RBC senescence were quantified after the incubation with SCD plasma samples. The physiologic in-flow adhesion was investigated on senescent RBCs, an in vitro technic into biochips that mimic adherence of RBCs during the occlusive events of SCD.
Senescence markers on AA RBCs, together with their in-flow adhesion to the plasma-bridging protein thrombospondin, were associated with the clinical status of the SCD patients from whom plasma was obtained. In these experiments, the highest values were obtained for SCD acute plasma samples. Adhesion of senescent RBCs into biochips, which is not reversed by a pre-treatment with recombinant Annexin V, can be reproduced with the use of chemical agents acting on RBC membrane channels that regulate either Ca entry or modulating RBC hydration.
We found that markers on red cells are correlated, and that the senescence induced by SCD plasma provokes the adhesion of RBCs to the vessel wall protein thrombospondin. In-flow adhesion of senescent red cells after plasma co-incubations can be reproduced with the use of modulators of RBC membrane channels; activating the Piezo1 Ca mechanosensitive channel provokes RBC adhesion of normal (non-senescent) RBCs, while blocking the Ca-dependent K Gardos channel, can reverse it. Clinically modulating the RBC adhesion to vascular wall proteins might be a promising avenue for the treatment of painful occlusive events in SCD.
输血仍然是治疗镰状细胞病(SCD)阻塞性发作和疼痛危象的关键治疗方法。在这种临床情况下,供体的红细胞(RBC)和输注给患者的红细胞可能会受到受者血液中血浆成分的影响。衰老损伤标志物在输血后出现在红细胞上,缩短了 RBC 在循环中的寿命。在 SCD 的特定情况下,衰老信号也可以触发疾病特有的阻塞性疼痛事件。这项工作是在我们之前的数据基础上进行的,这些数据描述了一种 RBC 衰老过程,在受到 SCD 病理血浆的挑战后,可以迅速检测到这种衰老过程。在这种临床情况下,我们希望进一步探讨与衰老相关的 AA RBC 损伤的特征和生理后果,因为输血后 RBC 引起的损伤可能对 SCD 患者产生不良后果。
来自 SCD 患者的急性症状(n=20)或稳定期疾病(n=34)的血浆样本与供体 AA RBC 在血液单位中共同孵育 24 至 48 小时。用 SCD 血浆样本孵育后,定量检测标记 RBC 衰老的特异性标志物。在衰老 RBC 上研究了生理内流黏附,这是一种在生物芯片上模拟 SCD 闭塞事件中 RBC 黏附的体外技术。
AA RBC 上的衰老标志物及其与从获得血浆的 SCD 患者的临床状况相关。在这些实验中,从 SCD 急性血浆样本中获得了最高值。用化学试剂处理 RBC 膜通道来调节 Ca 内流或调节 RBC 水合作用,用重组 Annexin V 预处理不能逆转的衰老 RBC 的内流黏附,可通过使用这些化学试剂在生物芯片上再现。
我们发现红细胞上的标志物是相关的,SCD 血浆诱导的衰老会引起 RBC 与血管壁蛋白血栓调节蛋白的黏附。用调节 RBC 膜通道的调节剂可以再现衰老 RBC 在血浆共孵育后的内流黏附;激活 Piezo1 Ca 机械敏感通道会引起正常(非衰老)RBC 的黏附,而阻断 Ca 依赖性 K Gardos 通道则会逆转这种黏附。临床上调节 RBC 与血管壁蛋白的黏附可能是治疗 SCD 疼痛性阻塞性事件的一种有前途的方法。